Skip to main content
BioSyent Inc. logo

BioSyent Inc. — Investor Relations & Filings

Ticker · RX ISIN · CA0906901081 TSXV Manufacturing
Filings indexed 411 across all filing types
Latest filing 2021-12-13 Regulatory Filings
Country CA Canada
Listing TSXV RX

About BioSyent Inc.

https://www.biosyent.com/

BioSyent Inc. is a profitable, growth-oriented specialty pharmaceutical company focused on enhancing patient lives by addressing unmet medical needs. The company's primary business model involves sourcing, in-licensing, and acquiring innovative pharmaceutical and healthcare products globally for development and commercialization. BioSyent markets a diverse portfolio of products, including prescription, over-the-counter, and behind-the-counter options, primarily serving markets in Canada and select international regions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-12-13 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2021-11-18 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 90% confidence The document contains only references to omitted pictures and no textual content or financial data. It is extremely short (324 characters) and does not contain any report, announcement, or detailed information. Given the lack of content, it cannot be classified as a substantive report or announcement. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings without clear classification.
2021-11-18 English
Interim financial statements/report – English.pdf
Regulatory Filings
2021-11-18 English
Interim MD&A - English.pdf
Regulatory Filings
2021-11-18 English
News release - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management’s discussion and analysis – November 9, 2021' and contains detailed discussion of the company's financial condition, operating results, and significant events for the three and six months ended September 30, 2021. It references the Interim Condensed Consolidated Financial Statements for the same period, indicating it is an interim or quarterly report. The content includes substantive financial data, analysis of business segments, and forward-looking statements typical of an Interim / Quarterly Report. The document length is 15,000 characters, which is consistent with a full report rather than a brief announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2022
2021-11-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.